Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Regeneron (REGN) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spyre Therapeutics (SYRE)
JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Spyre Therapeutics today and set a price target of $64.00. The company’s shares closed last Friday at $51.29.
According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of
Spyre Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $65.22, which is a 26.9% upside from current levels. In a report issued on April 9, LifeSci Capital also maintained a Buy rating on the stock with a $64.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Regeneron (REGN)
In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Regeneron. The company’s shares closed last Friday at $748.87.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $876.36 average price target, which is a 13.6% upside from current levels. In a report issued on March 31, Piper Sandler also initiated coverage with a Buy rating on the stock with a $875.00 price target.
Read More on SYRE:
Disclaimer & DisclosureReport an Issue
- Spyre Therapeutics Reports Positive Phase 2 SKYLINE Results
- Spyre Therapeutics reports SPY001 meets primary endpoint
- Damora names Peter Harwin chairman, appoints Spyre Therapeutics CEO to board
- Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline
- Spyre Therapeutics price target raised to $92 from $70 at Stifel
